Translation of the instructions can be
GLUCOSE-DARNYTSYA solution for injection 400 mg/ml
Instruction
For medical use of the medicinal product
Composition:
Active ingredient: glucose;
1 ml of solution contains 400 mg of glucose monohydrate;
Excipients: sodium chloride, diluted hydrochloric acid, water for injections.
Dosage form.
Solution for injection.
Main physicochemical properties: clear colorless or slightly yellowish liquid.
Pharmacotherapeutic group.
Intravenous solutions. Carbohydrates. ATC code B05C X01.
Pharmacological properties.
Pharmacodynamics.
Carbohydrate nutrition. Glucose provides substrate replenishment of energy expenditure, activates metabolic processes in the body. 40% glucose solution as a hypertonic solution increases the osmotic pressure of the blood, resulting in increased movement of fluid from tissues into the blood; improves the antitoxic function of the liver, increases myocardial contractility, and increases diuresis.
Pharmacokinetics.
After intravenous administration, glucose enters the organs and tissues, where it is phosphorylated, turning into glucose-6-phosphate, which is actively involved in various metabolic processes in the body. Glucose reserves are deposited in tissue cells in the form of glycogen.
Clinical characteristics.
Indication.
Hypoglycemia.
Contraindication.
Glucose solution 40% is contraindicated for use in patients with:
intracranial and intraspinal hemorrhages, ischemic stroke, except for conditions associated with hypoglycemia; severe dehydration, including alcoholic delirium; hypersensitivity to glucose and other components of the drug, allergy to corn and its products; diabetes mellitus and other conditions accompanied by hyperglycemia; anuria; glucose-galactose malabsorption syndrome.
The drug should not be administered simultaneously with blood products.
Interaction with other drugs and other types of interactions.
Diuretics and furosemide. Under the influence of these drugs, glucose tolerance decreases.
Insulin promotes the entry of glucose into peripheral tissues, stimulates the formation of glycogen, and the synthesis of proteins and fatty acids.
Pyrazinamide. Glucose solution reduces the toxic effects of pyrazinamide on the liver.
Digitalis preparations. The introduction of a large volume of glucose solution contributes to the development of hypokalemia, which increases the toxicity of simultaneously used digitalis preparations.
Application features.
Glucose solutions should be used with caution in patients with impaired carbohydrate tolerance of any origin, severe malnutrition, thiamine deficiency, hypophosphatemia, hemodilution, sepsis, trauma, shock, metabolic acidosis, or severe dehydration.
Monitor fluid and electrolyte balance and serum glucose levels.
With prolonged intravenous use of the drug, blood sugar levels should be monitored. For better glucose absorption in normoglycemic states, it is advisable to combine the administration of the drug with the administration of short-acting insulin (subcutaneously) at the rate of 1 U per 4-5 g of glucose (dry matter).
It is not recommended to prescribe the drug in the acute period of severe traumatic brain injury, in acute cerebral circulation disorders, since the drug may increase damage to brain structures and worsen the course of the disease (except in cases of correction of hypoglycemia).
In case of hypokalemia, the administration of the drug must be combined with simultaneous correction of potassium deficiency due to the risk of worsening hypokalemia; in case of hypotonic dehydration - with simultaneous administration of hypertonic saline solutions.
Do not apply the solution subcutaneously or intramuscularly.
The contents of the ampoule can only be used for one patient; after breaking the seal of the ampoule, the unused portion of the ampoule contents must be discarded.
This medicinal product contains sodium. If the patient is on a controlled sodium diet, caution should be exercised when using this medicinal product.
Use during pregnancy or breastfeeding.
The use of the drug in pregnant women with normoglycemia can lead to fetal hyperglycemia, causing metabolic acidosis in him. The latter is important to consider, especially when fetal distress or hypoxia is already caused by other perinatal factors.
Intravenous glucose administration to the mother during labor may affect intrauterine insulin production, causing the risk of fetal hyperglycemia and metabolic acidosis or hypoglycemia in the newborn due to the “ricochet phenomenon”.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Didn't study.
Method of administration and doses.
Intravenously, very slowly for adults, 20-40-50 ml per injection.
If necessary, administer by drip at a rate of up to 30 drops per minute (1.5 ml/kg/h), up to 300 ml per day.
The maximum daily dose for adults is 15 ml/kg and should not exceed 1000 ml.
Children.
The medicine should be used in children only as prescribed and under the supervision of a doctor.
Symptoms: with an overdose of the drug, hyperglycemia, glycosuria, increased blood osmotic pressure (up to the development of hyperglycemic hyperosmolar coma), hyperhydration, electrolyte imbalance develop.
Treatment. The drug should be discontinued and insulin should be administered at the rate of 1 unit for every 0.45-0.9 mmol of blood glucose until the blood glucose level reaches 9 mmol/l. The glucose level should be reduced gradually. Infusion of balanced salt solutions should be carried out simultaneously with the administration of insulin. If necessary, symptomatic treatment should be prescribed.
Adverse reactions.
Gastrointestinal: polydipsia, nausea.
From the kidneys and urinary system: polyuria, glycosuria.
From the side of metabolism: hyperglycemia, hypokalemia, hypophosphatemia, hypomagnesemia, acidosis.
On the part of the immune system: allergic reactions, including fever, skin rashes, angioedema, shock.
General disorders and administration site conditions: hypervolemia, electrolyte imbalance.
Administration of glucose in the setting of thiamine (vitamin B1) deficiency, including in patients with alcoholic delirium, may precipitate deficiency states such as Wernicke's encephalopathy. In severely malnourished patients, sodium retention, edema, pulmonary edema, and congestive heart failure may occur.
Injection site reactions including injection site pain, vein irritation, phlebitis, venous thrombosis.
In case of adverse reactions, the solution should be discontinued, the patient assessed and appropriate treatment provided. The remaining solution should be stored for further analysis.
Expiration date.
3 years.
Storage conditions.
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze.
Keep out of reach of children.
Incompatibility.
Glucose is incompatible in solutions with aminophylline, soluble barbiturates, erythromycin, hydrocortisone, warfarin, kanamycin, soluble sulfonamides, cyanocobalamin. should not be administered in the same syringe with hexamethylenetetramine, because glucose is a strong oxidizer. it is not recommended to mix in the same syringe with alkaline solutions: with general anesthetics and hypnotics, because their activity is reduced, solutions of alkaloids; inactivates streptomycin, reduces the effectiveness of nystatin.
Packaging.
10 ml or 20 ml in an ampoule; 5 or 10 ampoules in a pack.
Vacation category.
According to the recipe.
Producer.
Chao "Darnitsa Pharmaceutical Company".
Location of the manufacturer and address of its place of business.
Ukraine, 02093, Kyiv, Boryspilska St., 13.
GLUCOSE-DARNYTSYA solution for infusions 50 mg/ml
Instruction
For medical use of the medicinal product
Composition:
Active ingredient: glucose monohydrate;
1 ml of solution contains glucose monohydrate 50 mg;
excipient: water for injections.
Dosage form.
Solution for infusion.
Main physicochemical properties: clear colorless liquid.
Pharmacotherapeutic group.
Blood substitutes and perfusion solutions. ATS code B05C X01.
Pharmacological properties.
Pharmacodynamics.
Glucose solution 5% isotonic with blood plasma and when administered intravenously replenishes the volume of circulating blood, when it is lost it is a source of nutrients, and also helps to remove poison from the body. Glucose provides substrate replenishment of energy expenditure. When administered intravenously, it activates metabolic processes, improves the antitoxic function of the liver, enhances myocardial contractile activity, dilates blood vessels, and increases diuresis.
Pharmacokinetics.
After administration, it is rapidly distributed in body tissues. It is excreted by the kidneys.
Clinical characteristics.
Indication.
Hyper- and isotonic dehydration; to prevent water and electrolyte balance disorders in children during surgical interventions; intoxication; hypoglycemia; used as a solvent for other compatible drug solutions.
Contraindication.
Hyperglycemia. Hypersensitivity to dextrose.
The drug should not be administered simultaneously with blood products.
Interaction with other drugs and other types of interactions.
When used simultaneously with thiazide diuretics and furosemide, their ability to affect serum glucose levels should be taken into account.
Insulin promotes the entry of glucose into peripheral tissues.
Glucose solution reduces the toxic effects of pyrazinamide on the liver.
The introduction of a large volume of glucose solution contributes to the development of hypokalemia, which increases the toxicity of digitalis preparations.
The drug Glucose-Darnitsa is incompatible in solutions with aminophylline, soluble barbiturates, hydrocortisone, kanamycin, soluble sulfonamides, and cyanocobalamin.
Application features.
The drug should be used with great caution in patients with intracranial and intraspinal hemorrhages.
With prolonged use of the drug, blood glucose levels should be monitored.
To prevent plasma hypoosmolarity, 5% glucose solution can be combined with the administration of isotonic sodium chloride solution.
The contents of the vial may be used for one patient only. Once the seal of the bottle or polyethylene vial is broken, the unused portion of the contents of the bottle or vial must be disposed of.
Use during pregnancy or breastfeeding.
The medicine can be used according to indications.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Data are missing due to the exclusive use of the drug in a hospital setting.
Method of administration and doses.
The drug is administered intravenously by drip. The dose for adults is up to 1500 ml per day. The maximum daily dose for adults is 2000 ml per day. If necessary, the maximum rate of administration for adults is 150 drops per minute (500 ml / h).
Children.
The dose for children depends on age, body weight, condition, and laboratory parameters.
Overdose.
Possible increased manifestations of adverse reactions.
Hyperglycemia and hypotonic hyperhydration may develop. In case of drug overdose, symptomatic treatment and administration of regular insulin preparations are prescribed.
Adverse reactions.
From the gastrointestinal tract: very rarely - nausea of central origin.
From the side of metabolism: electrolyte imbalance and general reactions of the body that occur during massive infusions:
hypokalemia; hypophosphatemia; hypomagnesemia; hyponatremia; hypervolemia; hyperglycemia.
On the part of the immune system: allergic reactions (hyperthermia, skin rashes, angioedema, shock).
In case of adverse reactions, the solution should be stopped, the patient's condition assessed and assistance provided.
Expiration date.
2 years.
Storage conditions.
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze.
Keep out of reach of children.
Incompatibility.
The drug Glucose-Darnitsa is incompatible in solutions with aminophylline, soluble barbiturates, erythromycin, hydrocortisone, warfarin, kanamycin, soluble sulfonamides, and cyanocobalamin.
Do not use in the same system during, before or after blood transfusion due to the possibility of pseudoagglutination.
Packaging.
200 ml or 400 ml in bottles.
Vacation category.
According to the recipe.
Producer.
Chao "Darnitsa Pharmaceutical Company".
Location of the manufacturer and address of its place of business.
Ukraine, 02093, Kyiv, Boryspilska St., 13.
